A landmark nationwide study of 3.8 million births in South Korea reveals that taking prescription sleep medications during pregnancy does not increase a child’s long-term risk of developing psychiatric or neurodevelopmental disorders.
Pregnancy brings plenty of midnight tossing and turning, yet reaching for a prescription sleeping pill often triggers intense parental guilt. With insomnia symptoms affecting up to 23% of adults in South Korea and nearly 90% of diagnosed patients receiving prescription sleep aids, expectant mothers and their doctors have long worried that sedatives might quietly rewire a developing fetal brain.
Now, massive population data published in The BMJ delivers a collective sigh of relief for sleepless families. As senior study author Ju-Young Shin, PhD, and colleagues report, when researchers accounted for shared family genetics and home environments, the supposed link between prenatal sedatives and childhood mental health conditions vanished completely.
Background And The Clinical Dilemma Of Prenatal Insomnia
Untreated maternal insomnia and anxiety pose proven dangers to fetal health, forcing clinicians into a high-stakes balancing act between maternal relief and medication caution.
Insomnia is notoriously common, with symptoms affecting 17% to 23% of the general South Korean population and surging even higher during gestation. In South Korea, 89.9% of patients treated for insomnia receive prescription drugs, primarily zolpidem at over 60% and benzodiazepines at 30% to 40%.
Both benzodiazepines and non-benzodiazepine Z-hypnotics cross the placenta and act on the GABAA receptor pathway, which helps regulate early brain signaling. Because of this biological mechanism, doctors have historically hesitated to prescribe sedatives to expectant mothers.
Yet leaving severe sleeplessness or anxiety untreated isn’t a risk-free option either, as gestational insomnia correlates with preterm birth, pre-eclampsia, gestational diabetes, and postpartum depression. Ju-Young Shin, PhD, a professor at Sungkyunkwan University in Seoul, noted that “clinicians face a challenging dilemma when treating these conditions in pregnant women: untreated maternal psychiatric symptoms can adversely affect both mother and child, but drug treatments are used cautiously because of potential fetal risks.”
Related: Top 10 Most Unusual Pregnancy Cravings: Exploring the Strange, Gross, and Surprising
Study Design And Nationwide Cohort Methods
Researchers led by Yongtai Cho and Ju-Young Shin analyzed over 3.8 million live births from South Korea’s National Health Information Database to separate medication effects from underlying family genetics.
The research team tracked 3,809,949 children born between April 2010 and December 2022, following their medical records through December 2023 for a median of 6.85 years. About 2.5% of those children, 94,482 infants in total, were prenatally exposed to benzodiazepines or Z-hypnotics, while 3,715,467 remained unexposed.
To prevent maternal health history from skewing the results, the authors applied propensity-score overlap weighting across 44 distinct health and socioeconomic variables. They also compared exposed children against 147,307 children born to mothers who used sleep aids 180 to 91 days prior to conception but stopped before pregnancy.
Most importantly, the team ran a sibling-controlled analysis comparing 33,370 prenatally exposed children directly against 37,574 unexposed brothers and sisters from the exact same households.
Latest Developments From the Sibling-Controlled Analysis
While surface-level comparisons initially hinted at a 15% higher psychiatric risk, comparing siblings within the same family proved the medications themselves were not to blame.
At first glance, the raw numbers looked concerning: by age 13, cumulative psychiatric diagnoses reached 19.2% among exposed children, compared to 16.5% among children of past users and 13.8% in the unexposed group. Standard population models suggested a modestly elevated hazard ratio (HR 1.15, 95% CI 1.13–1.18) for exposed offspring compared with unexposed peers.
However, once the sibling-controlled analysis accounted for shared genetics and parenting environments, that elevated risk dropped to null (HR 0.99, 95% CI 0.94–1.04). In short, the inherited family predisposition toward anxiety or insomnia, not the pill bottle, drove the initial spike.
Across 12 individual psychiatric and neurodevelopmental categories, including autism spectrum disorder, ADHD, intellectual disability, mood and anxiety disorders, tic disorders, and behavioral conditions, researchers found zero increased risk. Intriguingly, sibling models showed lower rates of schizophrenia spectrum disorder and eating disorders, though the authors cautioned that small case counts likely explain those dips.
Scientific And Regulatory Context Across Pregnancy Trimesters
Although overall neuropsychiatric safety looks reassuring, slightly elevated trends in late pregnancy and prolonged use mean non-drug therapies remain the first-line standard.
Because unplanned pregnancies are common, many women accidentally take sleeping pills during their first weeks of gestation before realizing they are pregnant. For these early exposures, the Korean data offer strong peace of mind.
Still, subgroup data showed slightly higher, though statistically non-significant, point estimates when mothers took sedatives during the second half of pregnancy (after week 20) or used Z-hypnotics for 30 days or longer. In a linked BMJ editorial, Hyesung Lee, PhD, of Kangwon National University, urged careful interpretation, noting that “this study covers psychiatric diagnoses among liveborn offspring and cannot be taken as establishing overall perinatal safety—it does not inform risks of pregnancy loss, congenital malformations, or neonatal outcomes that also influence treatment decisions.”
Lee and colleagues emphasized that “reassurance should therefore remain outcome specific rather than global.” Clinical guidelines from the American College of Obstetricians and Gynecologists (ACOG) and recent 2026 stepped-care algorithms agree: Cognitive Behavioral Therapy for Insomnia (CBT-I) and sleep hygiene come first, while necessary medications should use the lowest effective dose for the shortest duration.
Why This Matters For Maternal Mental Health
Replacing blanket fear with solid epidemiological evidence empowers doctors and pregnant patients to make calmer, individualized treatment decisions.
Despite CBT-I being the gold standard for insomnia, psychotherapy claims in South Korean outpatient settings remain low, rising from just 3.20% in 2015 to 9.14% in 2019, meaning many women rely on prescriptions during acute mental health crises. ACOG guidelines explicitly warn against abruptly withholding or discontinuing necessary mental health medications due to pregnancy status alone.
By proving that genetic and environmental factors explain the apparent childhood psychiatric risks, this study removes a major source of stigma for mothers who genuinely need short-term pharmacological support.
The Bottom Line For Sleepless Expectant Parents
Prenatal exposure to benzodiazepines or Z-hypnotics does not raise a child’s risk of developing psychiatric disorders, though behavioral therapies and short-term dosing remain best practice.
Expectant mothers who took prescription sleep meds early in pregnancy can rest easier knowing their child’s long-term mental health isn’t jeopardized by those pills. When severe insomnia strikes during pregnancy, patients and obstetricians can now weigh treatment options using real-world evidence rather than worst-case assumptions.
How can healthcare systems make non-drug sleep therapies like CBT-I more accessible to expectant mothers so fewer families face this medication dilemma in the first place?
